NASDAQ / LIVE COMPANY INTELLIGENCE

Revolution Medicines, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERRVMD
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / RVMD COVERAGE

What’s moving Revolution Medicines, Inc. now

Current reporting with the operating signal separated from the noise.

01
Revolution Medicines, Inc.: European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process

Revolution Medicines, Inc.: European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process

The story matters when it changes Revolution Medicines, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript

The story matters when it changes Revolution Medicines, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Investors are testing whether Revolution Medicines, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now?

Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now?

Investors are testing whether Revolution Medicines, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript

Investors are testing whether Revolution Medicines, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest RVMD filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-05 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-25 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-22 · Period 2026-06-18SEC ↗8-KMaterial company eventFiled 2026-05-06 · Period 2026-05-06SEC ↗8-KMaterial company eventFiled 2026-04-17 · Period 2026-04-14SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-27 · Period 2026-06-18SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Revolution Medicines, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.